Greenwich LifeSciences, Inc. cotiza a 15.50 USD y tiene una capitalización bursátil de $228M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer…
| Métrica | GLSI | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -5480.6% | -40.4% | -5440.2% |
| ROA | -313.3% | -32.0% | -281.3% |
| Current Ratio | 1.06 | 2.84 | -1.78 |
| Debt / Equity | — | 0.28 | — |